425 related articles for article (PubMed ID: 30406374)
1. Apoptosis of tumor-infiltrating T lymphocytes: a new immune checkpoint mechanism.
Zhu J; Petit PF; Van den Eynde BJ
Cancer Immunol Immunother; 2019 May; 68(5):835-847. PubMed ID: 30406374
[TBL] [Abstract][Full Text] [Related]
2. Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes.
Zhu J; Powis de Tenbossche CG; Cané S; Colau D; van Baren N; Lurquin C; Schmitt-Verhulst AM; Liljeström P; Uyttenhove C; Van den Eynde BJ
Nat Commun; 2017 Nov; 8(1):1404. PubMed ID: 29123081
[TBL] [Abstract][Full Text] [Related]
3. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
4. Obesity-Associated Myeloid-Derived Suppressor Cells Promote Apoptosis of Tumor-Infiltrating CD8 T Cells and Immunotherapy Resistance in Breast Cancer.
Gibson JT; Orlandella RM; Turbitt WJ; Behring M; Manne U; Sorge RE; Norian LA
Front Immunol; 2020; 11():590794. PubMed ID: 33123173
[TBL] [Abstract][Full Text] [Related]
5. Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma.
Reichert TE; Strauss L; Wagner EM; Gooding W; Whiteside TL
Clin Cancer Res; 2002 Oct; 8(10):3137-45. PubMed ID: 12374681
[TBL] [Abstract][Full Text] [Related]
6. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma.
Bennett MW; O'Connell J; O'Sullivan GC; Brady C; Roche D; Collins JK; Shanahan F
J Immunol; 1998 Jun; 160(11):5669-75. PubMed ID: 9605174
[TBL] [Abstract][Full Text] [Related]
7. Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell-expressed FasL.
Sinha P; Chornoguz O; Clements VK; Artemenko KA; Zubarev RA; Ostrand-Rosenberg S
Blood; 2011 May; 117(20):5381-90. PubMed ID: 21450901
[TBL] [Abstract][Full Text] [Related]
8. Targeting novel inhibitory receptors in cancer immunotherapy.
Ding QQ; Chauvin JM; Zarour HM
Semin Immunol; 2020 Jun; 49():101436. PubMed ID: 33288379
[TBL] [Abstract][Full Text] [Related]
9. Effects of FasL expression in oral squamous cell cancer.
Fang L; Sun L; Hu FF; Chen QE
Asian Pac J Cancer Prev; 2013; 14(1):281-5. PubMed ID: 23534738
[TBL] [Abstract][Full Text] [Related]
10. E2f2 Attenuates Apoptosis of Activated T Lymphocytes and Protects from Immune-Mediated Injury through Repression of Fas and FasL.
Mustafa N; Mitxelena J; Infante A; Zenarruzabeitia O; Eriz A; Iglesias-Ara A; Zubiaga AM
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008734
[TBL] [Abstract][Full Text] [Related]
11. CD8+ tumor-infiltrating lymphocytes are primed for Fas-mediated activation-induced cell death but are not apoptotic in situ.
Radoja S; Saio M; Frey AB
J Immunol; 2001 May; 166(10):6074-83. PubMed ID: 11342625
[TBL] [Abstract][Full Text] [Related]
12. On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
Greil R; Egle A; Villunger A
Leuk Lymphoma; 1998 Nov; 31(5-6):477-90. PubMed ID: 9922038
[TBL] [Abstract][Full Text] [Related]
13. Regulating the suppressors: apoptosis and inflammation govern the survival of tumor-induced myeloid-derived suppressor cells (MDSC).
Ostrand-Rosenberg S; Sinha P; Chornoguz O; Ecker C
Cancer Immunol Immunother; 2012 Aug; 61(8):1319-25. PubMed ID: 22546994
[TBL] [Abstract][Full Text] [Related]
14. Resistance to Fas (APO-1/CD95)-mediated apoptosis and expression of Fas ligand in esophageal cancer: the Fas counterattack.
O'Connell J; Bennett MW; O'Sullivan GC; Collins JK; Shanahan F
Dis Esophagus; 1999; 12(2):83-9. PubMed ID: 10466039
[TBL] [Abstract][Full Text] [Related]
15. Immunosensitization of prostate carcinoma cell lines for lymphocytes (CTL, TIL, LAK)-mediated apoptosis via the Fas-Fas-ligand pathway of cytotoxicity.
Frost P; Ng CP; Belldegrun A; Bonavida B
Cell Immunol; 1997 Aug; 180(1):70-83. PubMed ID: 9316641
[TBL] [Abstract][Full Text] [Related]
16. Altered mechanisms of apoptosis in colon cancer: Fas resistance and counterattack in the tumor-immune conflict.
O'Connell J; Bennett MW; Nally K; Houston A; O'Sullivan GC; Shanahan F
Ann N Y Acad Sci; 2000 Jun; 910():178-92; discussion 193-5. PubMed ID: 10911913
[TBL] [Abstract][Full Text] [Related]
17. The role of the Fas/FasL signaling pathway in environmental toxicant-induced testicular cell apoptosis: An update.
Wang M; Su P
Syst Biol Reprod Med; 2018 Apr; 64(2):93-102. PubMed ID: 29299971
[TBL] [Abstract][Full Text] [Related]
18. Overcoming Tumor-Induced Immune Suppression: From Relieving Inhibition to Providing Costimulation with T Cell Agonists.
Emerson DA; Redmond WL
BioDrugs; 2018 Jun; 32(3):221-231. PubMed ID: 29637478
[TBL] [Abstract][Full Text] [Related]
19. Studies of the mechanism of cytolysis by tumour-infiltrating lymphocytes.
Hishii M; Kurnick JT; Ramirez-Montagut T; Pandolfi F
Clin Exp Immunol; 1999 Jun; 116(3):388-94. PubMed ID: 10361224
[TBL] [Abstract][Full Text] [Related]
20. Restored T-cell activation mechanisms in human tumour-infiltrating lymphocytes from melanomas and colorectal carcinomas after exposure to interleukin-2.
De Paola F; Ridolfi R; Riccobon A; Flamini E; Barzanti F; Granato AM; Mordenti GL; Medri L; Vitali P; Amadori D
Br J Cancer; 2003 Jan; 88(2):320-6. PubMed ID: 12610520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
